Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Nordisk Goes On Offense, Says Its Levemir Insulin Is Safer Bet

This article was originally published in The Pink Sheet Daily

Executive Summary

As news of cancer risk for Lantus sinks in, Novo says it is prepared to pick up orders for patients who want to switch.

You may also be interested in...



Sanofi Counts FDA As New Supporter In Lantus Cancer Scare

Due to "inconsistencies" in European studies, agency is struggling to determine if evidence of cancer risk "truly exists."

Sanofi Counts FDA As New Supporter In Lantus Cancer Scare

Due to "inconsistencies" in European studies, agency is struggling to determine if evidence of cancer risk "truly exists."

Will Sanofi's Lantus Survive Cancer Scare? Studies Suggest a Worrisome Link

But the data also suggest a higher cancer risk could be due to "patient characteristics," and not Lantus itself.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel